flow trial semaglutide kidney outcomes 2024 nejm hazard ratio in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical Top Stories in Nephrology 2024

Embody can prescribe branded medications but they dont dispense brand-name options

PET-CT scans combine two powerful imaging tools, giving doctors a detailed picture of whats happening in the body

BPC-157 is not approved for human use by the MHRA in the UK or the FDA in the US

Over 9 weeks of treatment, semaglutide led to reductions in some but not all measures of weekly consumption, significantly reduced weekly alcohol craving relative to placebo, and led to greater relative reductions in cigarettes per day in a subgroup of participants with current cigarette use

Your follicles aren't dead

Collagen supplementation in skin and orthopedic diseases